Author + information
- Received December 18, 2019
- Revision received March 18, 2020
- Accepted March 19, 2020
- Published online August 3, 2020.
- Jeremy Ben-Shoshan, MD, PhDa,b,
- Pavel Overtchook, MDa,c,
- Jean Buithieu, MDa,
- Negar Mousavi, MDa,
- Giuseppe Martucci, MDa,
- Marco Spaziano, MDa,
- Benoit de Varennes, MD, MSca,
- Kevin Lachapelle, MDa,
- James Brophy, MD, PhDa,
- Thomas Modine, MD, PhDd,
- Andreas Baumbach, MDe,
- Francesco Maisano, MDf,
- Bernard Prendergast, MDg,
- Corrado Tamburino, MD, PhDh,
- Stephan Windecker, MDc and
- Nicolo Piazza, MD, PhDa,∗ ()
- aMcGill University Health Center, McGill University, Montreal, Quebec, Canada
- bTel-Aviv Medical Center, Tel-Aviv University, Tel-Aviv, Israel
- cBern University Hospital, University of Bern, Bern, Switzerland
- dCentre Hospitalier Regional et Universitaire de Lille, Lille, France
- eBarts Heart Centre, Barts Health NHS, Queen Mary University, London, United Kingdom
- fUniversity Hospital of Zurich, University of Zurich, Zurich, Switzerland
- gSt. Thomas’ Hospital, London, United Kingdom
- hFerrarotto Hospital, University of Catania, Catania, Italy
- ↵∗Address for correspondence:
Dr. Nicolo Piazza, McGill University Health Centre, Cardiology Division, 1001 Decarie Boulevard, Montreal QC H4A 3J1, Canada.
• Selection and risk stratification for transcatheter edge-to-edge MV repair are based on surgical prognostic scores and technical feasibility.
• Clinical, structural, and procedural factors affect prognosis after transcatheter edge-to-edge MV repair and should be integrated in pre-procedural evaluation and follow-up.
• Better understanding of the factors that affect prognosis in patients undergoing transcatheter edge-to-edge MV repair might improve management of high-risk patients with severe MR.
Transcatheter edge-to-edge mitral valve repair is a viable alternative to surgery in patients with severe mitral regurgitation and high surgical risk. Yet the specific group of patients who would optimally benefit from this therapy remains to be determined. Selection of patients for transcatheter strategy is currently based on surgical prognostic scores and technical feasibility. Meanwhile, various clinical, anatomic, and procedural factors have been recently recognized as predictors of adverse outcomes following transcatheter edge-to-edge mitral valve repair, including device failure, recurrent mitral regurgitation, and mortality. Integration of these prognostic factors in the decision-making process of the heart team might improve patient management and outcomes. Herein, the authors review the different factors related to symptomatic status, comorbidity, serum biomarkers, echocardiographic findings, and procedural technique that have been identified as independent predictors of adverse outcome following transcatheter edge-to-edge mitral valve repair and discuss their potential application in everyday clinical practice.
Dr. Piazza is a consultant for Medtronic, HighLife, and MicroPor. Dr. Modine is a consultant and an advisory board member for Abbott. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the JACC: Cardiovascular Interventions author instructions page.
- Received December 18, 2019.
- Revision received March 18, 2020.
- Accepted March 19, 2020.
- 2020 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.